Edwards Lifesciences saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 63 to 74.
Can You Really Time The Stock Market?
This proprietary rating identifies technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an 80 or higher RS Rating as they launch their largest climbs. See if Edwards Lifesciences can continue to show renewed price strength and clear that threshold.
Edwards Lifesciences is still inside a buy range after breaking past a 78.75 buy point in a flat base. The proper buying range extends to 5% above the initial entry. Once a stock moves above that range, it's best to wait for it to set up another buying opportunity..
While earnings-per-share growth dropped in the company's most recently reported quarter from 16% to 8%, sales rose 12%, up from 6% in the previous report.
Edwards Lifesciences earns the No. 8 rank among its peers in the Medical-Products industry group. Hinge Health, Boston Scientific and Insulet are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
